| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdbfcb171ff808233241d169ed2923b7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate |
1996-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28c2e42ae89495c0d27f2b48fa186fb9 |
| publicationDate |
1997-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9720562-A1 |
| titleOfInvention |
Cisapride sustained release |
| abstract |
The present invention concerns pharmaceutical dosage forms comprising cisapride-(L)- tartrate or a precursor form thereof, contained in a porous structure consisting essentially of one or more polymers which are insoluble or practically insoluble in water or gastro-intestinal fluids and wherein the pores of the porous structure comprise a substance soluble in water or gastro-intestinal fluids adjacent to the surface of the dosage form. The present invention is further concerned with processes for preparing such pharmaceutical dosage forms and with the use of these pharmaceutical dosage forms as a medicine, especially in treating gastro-intestinal disorders, more particularly gastro-oesephagal reflux disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9823259-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000080028-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6110494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9829095-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9829095-A3 |
| priorityDate |
1995-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |